Ultragenyx Pharmaceutical
RARE
RARE
165 hedge funds and large institutions have $2.5B invested in Ultragenyx Pharmaceutical in 2018 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 70 increasing their positions, 39 reducing their positions, and 21 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
2.89% less ownership
Funds ownership: 101.54% → 98.65% (-2.9%)
89% less call options, than puts
Call options by funds: $1.03M | Put options by funds: $9.62M
Holders
165
Holding in Top 10
–
Calls
$1.03M
Puts
$9.62M
Top Buyers
| 1 | +$59.2M | |
| 2 | +$47.4M | |
| 3 | +$40.3M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$39.8M |
| 5 |
BlackRock
New York
|
+$25.4M |
Top Sellers
| 1 | -$13.5M | |
| 2 | -$12.9M | |
| 3 | -$6.73M | |
| 4 |
PC
Pier Capital
Stamford,
Connecticut
|
-$5.83M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$4.41M |